Morgan Stanley Sees 90% Probability of Biogen (BIIB) Moving 10%+ Higher Upon Receiving Alzheimer's Disease NCD Draft Coverage
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $363.00 price target on Biogen (NASDAQ: BIIB) ahead of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
